The WACC of Kuros Biosciences AG (KURN.SW) is 6.2%.
| Range | Selected | |
| Cost of equity | 4.80% - 7.60% | 6.20% |
| Tax rate | 7.10% - 9.70% | 8.40% |
| Cost of debt | 4.00% - 7.00% | 5.50% |
| WACC | 4.8% - 7.6% | 6.2% |
| Category | Low | High |
| Long-term bond rate | 1.0% | 1.5% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | 0.26 | 0.51 |
| Additional risk adjustments | 2.5% | 3.0% |
| Cost of equity | 4.80% | 7.60% |
| Tax rate | 7.10% | 9.70% |
| Debt/Equity ratio | 0.01 | 0.01 |
| Cost of debt | 4.00% | 7.00% |
| After-tax WACC | 4.8% | 7.6% |
| Selected WACC | 6.2% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for KURN.SW:
cost_of_equity (6.20%) = risk_free_rate (1.25%) + equity_risk_premium (5.60%) * adjusted_beta (0.26) + risk_adjustments (2.75%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.